CDK2 and leukemia: The derivatives of 4-benzoylamino-1H-pyrazole-3-carboxamide were recently shown as a potent CDK2 inhibitor that exhibited the highest anti-proliferative activities against cancer cell lines (e.g., A2058 melanoma and MV4-11 leukemia cell line) when compared to non-transformed human normal cell lines [41].